यह सेवा आपके क्षेत्र में उपलब्ध नहीं है।

कंपनी की जानकारी

समीक्षाएं

Loading company information...

यह सेवा आपके क्षेत्र में उपलब्ध नहीं है।

Alpha Management Limited

संयुक्त अरब अमीरात

स्थापित किया गया

2007 (19 साल)

स्थापित

आखिरी बार ऑनलाइन: हाल की कोई गतिविधि नहीं

कृपया अपने विकल्पों पर ध्यानपूर्वक विचार करें और उस सेवा का चयन करें जो आपकी आवश्यकताओं को सबसे अच्छी तरह से पूरा करती हो।

वेबसाइट पर जाएं

बचें

द्वारा संचालित TrustFinance

सुरक्षा जानकारी

0.00

ट्रस्टफाइनेंस पर सत्यापन

0.00

ट्रैफिक और सहभागिता

1.67

सोशल लुकअप

0.00

द्वारा संचालित TrustFinance

व्यवस्थित

TrustFinance

(968 समीक्षाएं)

Singapore

2020

(5 वर्ष)

सुरक्षा जानकारी :

कंपनी ने जानकारी प्रदान नहीं की है।

सुरक्षा जानकारी

चेतावनी

यह कंपनी वर्तमान में अप्रमाणित.

कृपया संभावित जोखिमों से सावधान रहें!

लाइसेंस

ए ग्रेड लाइसेंस

विश्व स्तर पर प्रसिद्ध नियामकों द्वारा जारी किए गए, ये लाइसेंस सख्त अनुपालन, फंड सेग्रीगेशन, बीमा और नियमित ऑडिट के माध्यम से उच्चतम व्यापारी सुरक्षा सुनिश्चित करते हैं। विवाद समाधान और AML/CTF मानकों का पालन सुरक्षा को और बढ़ाता है।

बी ग्रेड लाइसेंस

सम्मानित क्षेत्रीय नियामकों द्वारा प्रदान किए गए, ये लाइसेंस फंड सेग्रीगेशन, वित्तीय रिपोर्टिंग और मुआवजा योजनाओं जैसे मजबूत सुरक्षा उपाय प्रदान करते हैं। हालांकि टियर 1 से थोड़ा कम सख्त, वे भरोसेमंद क्षेत्रीय सुरक्षा प्रदान करते हैं।

सी ग्रेड लाइसेंस

उभरते बाजारों में नियामकों द्वारा जारी किए गए, ये लाइसेंस न्यूनतम पूंजी आवश्यकताओं और AML नीतियों जैसे बुनियादी सुरक्षा प्रदान करते हैं। निरीक्षण कम कठोर है, इसलिए व्यापारियों को सावधानी बरतनी चाहिए और सुरक्षा उपायों को सत्यापित करना चाहिए।

डी ग्रेड लाइसेंस

न्यूनतम निरीक्षण वाले न्यायालयों से, इन लाइसेंसों में अक्सर फंड सेग्रीगेशन और बीमा जैसे महत्वपूर्ण सुरक्षा उपायों का अभाव होता है। परिचालन लचीलेपन के लिए आकर्षक होने पर, वे व्यापारियों के लिए उच्च जोखिम पैदा करते हैं।

कंपनी की जानकारी

जानिए Alpha Management Limited

और दिखाएं

कंपनी की जानकारी

जानिए Alpha Management Limited

Founded in 2009, Alpha Management Limited is a management company licensed and regulated by the Financial Services Commission (FSC) of Mauritius. The company specializes in creating, managing, and administering cross-border investment structures for a diverse clientele, including institutional investors, fund managers, and high-net-worth individuals. Its core mission is to provide bespoke, flexible, and efficient solutions in corporate structuring, fund administration, and private wealth management, leveraging Mauritius's position as an international financial center.

और दिखाएं

उद्योग

वित्तीय कानूनी सेवाप्राथमिक
वित्तीय निवेश
वित्तीय अन्य सेवा

सॉफ्टवेयर

कोई डेटा उपलब्ध नहीं है।

ऐसा लगता है कि यह अनुभाग खाली है। अपडेट्स के लिए जल्द ही वापस आएं!

संपर्क

सोशल

कंपनी ने अपनी जानकारी अपडेट नहीं की है।

जो उपयोगकर्ता Alpha Management Limited देखते हैं वे भी देखते हैं...

IUX

XM

FXGT

Deriv

Exness

IUX

XM

FXGT

Deriv

Exness

समाचार

TrustFinance खुफिया एजेंसी

अनुसंधान तिथि: Feb 14, 2026

The article discusses the evolving landscape of prime brokerage in the context of alternative investments, particularly hedge funds. It highlights the increasing complexity and sophistication of investment strategies, driven by market volatility and the growth of multi-manager funds. With assets under management in the hedge fund industry expected to reach USD 5 trillion by 2028, prime brokers must expand their capabilities to support diverse investment strategies. The article emphasizes the importance of fixed income financing, the rise of mega-funds, and the need for established prime brokers to provide access to both developed and emerging markets. It concludes that diversification is key for both funds and prime brokers to facilitate alpha generation and meet the demands of sophisticated investors.

The article discusses the evolving landscape of prime brokerage in the context of alternative investments, particularly hedge funds. It highlights the increasing complexity and sophistication of investment strategies, driven by market volatility and the growth of multi-manager funds. With assets under management in the hedge fund industry expected to reach USD 5 trillion by 2028, prime brokers must expand their capabilities to support diverse investment strategies. The article emphasizes the importance of fixed income financing, the rise of mega-funds, and the need for established prime brokers to provide access to both developed and emerging markets. It concludes that diversification is key for both funds and prime brokers to facilitate alpha generation and meet the demands of sophisticated investors.

AlphaSense is an AI-driven financial research platform that integrates both internal and external data sources, providing comprehensive insights for financial professionals. It offers features like generative AI tools, extensive content libraries, advanced search capabilities, and customizable dashboards to enhance research efficiency. The platform is designed for various financial sectors, including investment banking, asset management, and private equity, and has been recognized as a leader in the industry. AlphaSense combines premium external content with internal knowledge, enabling users to extract insights and make informed decisions quickly.

AlphaSense is an AI-driven financial research platform that integrates both internal and external data sources, providing comprehensive insights for financial professionals. It offers features like generative AI tools, extensive content libraries, advanced search capabilities, and customizable dashboards to enhance research efficiency. The platform is designed for various financial sectors, including investment banking, asset management, and private equity, and has been recognized as a leader in the industry. AlphaSense combines premium external content with internal knowledge, enabling users to extract insights and make informed decisions quickly.

Alpha Group International reported a 23% revenue growth to £135.6 million for 2024, with a profit before tax of £123.1 million, marking a 6% increase. The company's performance was significantly bolstered by £84 million in interest income from client balances. The new CEO, Clive Kahn, expressed confidence in the company's growth despite a challenging macroeconomic environment. The business is divided into three segments: Corporate, Private Markets, and Cobase, with notable revenue increases across all divisions. The board proposed a final dividend of 14.0 pence per share, raising the total dividend for 2024 to 18.2 pence, up from 16.0 pence in 2023.

Alpha Group International reported a 23% revenue growth to £135.6 million for 2024, with a profit before tax of £123.1 million, marking a 6% increase. The company's performance was significantly bolstered by £84 million in interest income from client balances. The new CEO, Clive Kahn, expressed confidence in the company's growth despite a challenging macroeconomic environment. The business is divided into three segments: Corporate, Private Markets, and Cobase, with notable revenue increases across all divisions. The board proposed a final dividend of 14.0 pence per share, raising the total dividend for 2024 to 18.2 pence, up from 16.0 pence in 2023.

Liminal BioSciences Inc. has completed a statutory plan of arrangement with Structured Alpha LP, whereby SALP acquired all outstanding common shares of Liminal not owned by it or its affiliates at a price of $8.50 per share. Following this arrangement, Liminal's shares will no longer be listed on the Nasdaq Capital Market, and the company will cease to be a reporting issuer under Canadian securities law. Liminal BioSciences focuses on developing small molecule therapeutics targeting GPCR pathways for various diseases, with ongoing clinical and preclinical programs.

Liminal BioSciences Inc. has completed a statutory plan of arrangement with Structured Alpha LP, whereby SALP acquired all outstanding common shares of Liminal not owned by it or its affiliates at a price of $8.50 per share. Following this arrangement, Liminal's shares will no longer be listed on the Nasdaq Capital Market, and the company will cease to be a reporting issuer under Canadian securities law. Liminal BioSciences focuses on developing small molecule therapeutics targeting GPCR pathways for various diseases, with ongoing clinical and preclinical programs.

The article presents a systematic review of controlled trials investigating the efficacy and safety of anti-tumour necrosis factor-alpha (TNF-α) agents in treating Behçet's disease (BD), specifically focusing on uveitis. The review included 13 studies with a total of 778 patients, showing that anti-TNF-α therapy significantly reduces relapse rates of uveitis compared to traditional immunosuppressant therapies. However, the evidence for the full spectrum of BD subtypes remains limited, highlighting the need for further research. The study emphasizes the importance of preventing relapses to avoid permanent vision impairment or blindness in BD patients.

The article presents a systematic review of controlled trials investigating the efficacy and safety of anti-tumour necrosis factor-alpha (TNF-α) agents in treating Behçet's disease (BD), specifically focusing on uveitis. The review included 13 studies with a total of 778 patients, showing that anti-TNF-α therapy significantly reduces relapse rates of uveitis compared to traditional immunosuppressant therapies. However, the evidence for the full spectrum of BD subtypes remains limited, highlighting the need for further research. The study emphasizes the importance of preventing relapses to avoid permanent vision impairment or blindness in BD patients.

ट्रस्टफाइनेंस एआई विश्लेषण द्वारा प्रदान किया गया

समीक्षाएं